113(top 1%)
papers
6.7K(top 1%)
citations
50(top 1%)
h-index
81(top 1%)
g-index
119
all documents
7.1K
doc citations
1.2K
citing journals

Top Articles

#TitleJournalYearCitations
1Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humansNature Medicine2004538
2The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosisPLoS Pathogens2008410
3Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationNature Communications2013256
4Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraProceedings of the National Academy of Sciences of the United States of America2005228
5ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in HumansMolecular Therapy2012196
6Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1Molecular Therapy2014188
7Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine VectorsPLoS ONE2012157
8Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine VectorsMolecular Therapy2011156
9Manslaughter by Fake Artesunate in Asia—Will Africa Be Next?PLoS Medicine2006141
10Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcriptionBMC Genomics2011135
11Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparisonLancet, The2006133
12Taking social relationships seriously: Lessons learned from the informed consent practices of a vaccine trial on the Kenyan CoastSocial Science and Medicine2008128
13Opa proteins and CEACAMs: pathways of immune engagement for pathogenicNeisseriaFEMS Microbiology Reviews2011127
14Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against MalariaJournal of Immunology2005123
15Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trialsTuberculosis2005114
16Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of AgePediatric Infectious Disease Journal2010114
17Fatal Plasmodium falciparum Malaria Causes Specific Patterns of Splenic Architectural DisorganizationInfection and Immunity2005111
18Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational studyBMJ: British Medical Journal2008108
19Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected IndividualsAmerican Journal of Respiratory and Critical Care Medicine2009107
20Prime-boost immunisation strategies for tuberculosisMicrobes and Infection2005103
21The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster ResponseJournal of Immunology2008101
22Synergistic DNA–MVA prime-boost vaccination regimes for malaria and tuberculosisVaccine200697
23Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea PigsInfection and Immunity200595
24Prime-boost strategies for malaria vaccine developmentJournal of Experimental Biology200389
25Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical TrialClinical Infectious Diseases201083
26Clinical and Microbiological Features of HIV-Associated Tuberculous Meningitis in Vietnamese AdultsPLoS ONE200882
27Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in KenyansPLoS ONE200882
28Transmission-Blocking Activities of Quinine, Primaquine, and ArtesunateAntimicrobial Agents and Chemotherapy200680
29Immune Inhibitory Ligand CD200 Induction by TLRs and NLRs Limits Macrophage Activation to Protect the Host from Meningococcal SepticemiaCell Host and Microbe201080
30Genetic diversity of Plasmodium vivax in Kolkata, IndiaMalaria Journal200674
31Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I TrialPLoS ONE201472
32Sensitivity of IFN-γ Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS ProgressionPLoS ONE200869
33Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countriesAnalyst, The201169
34Destabilisation and subsequent lysis of human erythrocytes induced by Plasmodium falciparum haem productsEuropean Journal of Haematology200568
35Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical TrialMolecular Therapy201468
36The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal primingImmunology200967
37Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteersVaccine200665
38Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural ExposurePLoS ONE201465
39Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan AdultsPLoS ONE201364
40Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in InfantsJAMA - Journal of the American Medical Association200563
41Limited Polymorphism in the Dihydropteroate Synthetase Gene ( dhps ) of Plasmodium vivax Isolates from ThailandAntimicrobial Agents and Chemotherapy200563
42Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAARTAids200663
43Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trialBMJ: British Medical Journal200662
44Quadrivalent meningococcal conjugate vaccinesVaccine200961
45Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85APLoS ONE200961
46Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccinesArchives of Disease in Childhood200757
47Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy TrialsPLoS ONE200757
48Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study designLancet Infectious Diseases, The200655
49Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and InfantsMolecular Therapy201652
50Micronutrient status in lactating mothers before and after introduction of fortified flour: cross-sectional surveys in Maela refugee campEuropean Journal of Nutrition201251